Snippe H, van Dam J E, van Houte A J, Willers J M, Kamerling J P, Vliegenthart J F
Infect Immun. 1983 Nov;42(2):842-4. doi: 10.1128/iai.42.2.842-844.1983.
A semisynthetic vaccine to Streptococcus pneumoniae type 3 has been developed. The hexasaccharide [leads to 3)GlcpA beta(1 leads to 4)Glcp beta(1 leads to]3 was isolated from a partial acid hydrolysate of the capsular polysaccharide S3. It was coupled to stearylamine by reductamination with NaCNBH3 and then incorporated into liposomes. These haptenated liposomes were tested for immunogenicity in mice. They induced protection to a lethal dose (25 50% lethal doses) of S. pneumoniae type 3 and gave rise to immunoglobulin M antibodies. No cross-protection was observed against S. pneumoniae type 11.
已研发出一种针对3型肺炎链球菌的半合成疫苗。从荚膜多糖S3的部分酸水解产物中分离出六糖[导致3)GlcpAβ(1导致4)Glcpβ(1导致]3。通过用NaCNBH3进行还原胺化将其与硬脂胺偶联,然后掺入脂质体中。对这些结合了半抗原的脂质体在小鼠中进行免疫原性测试。它们诱导对致死剂量(25个50%致死剂量)的3型肺炎链球菌产生保护作用,并产生免疫球蛋白M抗体。未观察到对11型肺炎链球菌的交叉保护作用。